Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OST003
MIFTS: 67

Osteonecrosis

Categories: Blood diseases, Bone diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Osteonecrosis

About this section

MalaCards integrated aliases for Osteonecrosis:

Name: Osteonecrosis 39 12 77 44 45 15 17
Aseptic Necrosis 12 30
Bone Necrosis 12 74
Avascular Necrosis of Bone 12

Classifications:

MalaCards categories:
Anatomical: Bone diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


Sources

Summaries for Osteonecrosis

About this section
MedlinePlus : 44 Osteonecrosis is a disease caused by reduced blood flow to bones in the joints. In people with healthy bones, new bone is always replacing old bone. In osteonecrosis, the lack of blood causes the bone to break down faster than the body can make enough new bone. The bone starts to die and may break down. You can have osteonecrosis in one or several bones. It is most common in the upper leg. Other common sites are your upper arm and your knees, shoulders and ankles. The disease can affect men and women of any age, but it usually strikes in your thirties, forties or fifties. At first, you might not have any symptoms. As the disease gets worse, you will probably have joint pain that becomes more severe. You may not be able to bend or move the affected joint very well. No one is sure what causes the disease. Risk factors include Long-term steroid treatment Alcohol abuse Joint injuries Having certain diseases, including arthritis and cancer Doctors use imaging tests and other tests to diagnose osteonecrosis. Treatments include medicines, using crutches, limiting activities that put weight on the affected joints, electrical stimulation and surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Osteonecrosis, also known as aseptic necrosis, is related to osteonecrosis of the jaw and legg-calve-perthes disease, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Osteonecrosis is BMP2 (Bone Morphogenetic Protein 2), and among its related pathways/superpathways are Selenium Micronutrient Network and Formation of Fibrin Clot (Clotting Cascade). The drugs Alendronate and Zoledronic Acid have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and testes, and related phenotypes are growth/size/body region and cardiovascular system

Disease Ontology : 12 An ischemic bone disease that results in necrosis located in bone.

Wikipedia : 77 Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to... more...

Sources

Related Diseases for Osteonecrosis

About this section

Diseases related to Osteonecrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 397)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis of the jaw 34.1 CYP2C8 FDPS VEGFA
2 legg-calve-perthes disease 32.7 COL2A1 SERPINC1 SERPINE1
3 thrombophilia 30.8 F2 MTHFR SERPINC1 SERPINE1
4 disseminated intravascular coagulation 30.3 F2 SERPINC1 SERPINE1
5 antiphospholipid syndrome 30.3 F2 MTHFR SERPINC1
6 myeloma, multiple 30.3 ABCB1 DKK1 TNF TNFRSF11B TNFSF11 VEGFA
7 osteomyelitis 30.3 ACP5 BMP2 TNF TNFSF11
8 protein s deficiency 30.2 F2 MTHFR SERPINC1
9 synovitis 30.2 TNF TNFRSF11B TNFSF11
10 purpura 30.1 F2 SERPINC1 TNF
11 sickle cell anemia 30.1 F2 MTHFR TNF
12 osteoporotic fracture 30.1 MTHFR TNFRSF11B
13 kummell's disease 30.0 DKK1 TNFRSF11B TNFSF11
14 thrombosis 30.0 F2 MTHFR SERPINC1 SERPINE1
15 antithrombin iii deficiency 30.0 F2 MTHFR SERPINC1
16 periodontal disease 29.9 TNF TNFRSF11B TNFSF11
17 protein c deficiency 29.9 F2 MTHFR SERPINC1
18 homocysteinemia 29.9 F2 MTHFR SERPINC1
19 villonodular synovitis 29.9 ACP5 TNFSF11
20 joint disorders 29.8 DKK1 TNF TNFSF11
21 arthropathy 29.8 TNF TNFRSF11B TNFSF11
22 renal osteodystrophy 29.8 BGLAP PTH TNFRSF11B
23 endosteal hyperostosis, autosomal dominant 29.7 BMP2 TNFRSF11B TNFSF11
24 paget's disease of bone 29.7 BGLAP TNFRSF11B TNFSF11
25 rheumatoid arthritis 29.7 ACP5 TNF TNFRSF11B TNFSF11 VEGFA
26 giant cell tumor 29.7 BGLAP TNFRSF11B TNFSF11
27 periodontitis 29.7 BGLAP RUNX2 TNF TNFRSF11B TNFSF11
28 pseudoarthrosis 29.6 BMP2 PTH
29 heart disease 29.3 F2 MTHFR SERPINC1 SERPINE1 TNF VEGFA
30 hyperparathyroidism 28.9 ACP5 BGLAP PTH TNFRSF11B
31 vascular disease 28.7 F2 MTHFR PLG SERPINC1 SERPINE1 TNF
32 osteoporosis 28.2 ACP5 BGLAP BMP2 DKK1 FDPS PTH
33 bone resorption disease 28.1 ACP5 BGLAP BMP2 DKK1 PTH RUNX2
34 bone disease 27.8 ACP5 BGLAP COL2A1 DKK1 PTH RUNX2
35 glucocorticoid-induced osteoporosis 27.8 ACP5 BGLAP BMP2 DKK1 PTH RUNX2
36 dysbaric osteonecrosis 12.5
37 avascular necrosis of femoral head, primary, 1 12.0
38 familial avascular necrosis of the femoral head 11.6
39 kohler's disease 11.4
40 kienbock's disease 11.4
41 freiberg's disease 11.4
42 osgood-schlatter's disease 11.3
43 panner disease 11.3
44 sinding-larsen-johansson disease 11.3
45 thiemann disease 11.1
46 gaucher disease, type iii 11.1
47 leukemia 10.5
48 inferior vena cava interruption 10.5 MTHFR SERPINE1
49 systemic lupus erythematosus 10.5
50 lupus erythematosus 10.5

Graphical network of the top 20 diseases related to Osteonecrosis:



Diseases related to Osteonecrosis
Sources

Symptoms & Phenotypes for Osteonecrosis

About this section

UMLS symptoms related to Osteonecrosis:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Osteonecrosis:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.37 ABCB1 BMP2 COL2A1 DKK1 F2 MTHFR
2 cardiovascular system MP:0005385 10.34 ABCB1 BMP2 COL2A1 F2 PLG PTH
3 homeostasis/metabolism MP:0005376 10.34 ABCB1 BMP2 COL2A1 DKK1 F2 MTHFR
4 hematopoietic system MP:0005397 10.29 ABCB1 BMP2 F2 PLG PTH RUNX2
5 immune system MP:0005387 10.29 ABCB1 BMP2 COL2A1 F2 PLG PTH
6 mortality/aging MP:0010768 10.24 ABCB1 BMP2 COL2A1 DKK1 F2 MTHFR
7 craniofacial MP:0005382 10.2 BMP2 COL2A1 DKK1 PTH RUNX2 TNF
8 digestive/alimentary MP:0005381 10.14 ABCB1 BMP2 COL2A1 F2 PLG RUNX2
9 limbs/digits/tail MP:0005371 10.13 BMP2 COL2A1 DKK1 MTHFR PTH RUNX2
10 integument MP:0010771 10.06 F2 MTHFR PLG RUNX2 SERPINE1 TNF
11 liver/biliary system MP:0005370 10.06 ABCB1 COL2A1 MTHFR PLG RUNX2 SERPINC1
12 nervous system MP:0003631 10.06 ABCB1 BMP2 COL2A1 DKK1 F2 MTHFR
13 reproductive system MP:0005389 9.96 ABCB1 BMP2 F2 MTHFR PLG RUNX2
14 respiratory system MP:0005388 9.81 COL2A1 DKK1 F2 PLG RUNX2 SERPINE1
15 skeleton MP:0005390 9.7 BMP2 COL2A1 DKK1 F2 MTHFR PTH
16 vision/eye MP:0005391 9.28 COL2A1 DKK1 MTHFR PLG RUNX2 SERPINC1
Sources

Drugs & Therapeutics for Osteonecrosis

About this section

Drugs for Osteonecrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 267)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2,Phase 1 66376-36-1, 121268-17-5 2088
2
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Propofol Approved, Investigational, Vet_approved Phase 4,Early Phase 1 2078-54-8 4943
8
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
9
Tocopherol Approved, Investigational Phase 4,Phase 3 1406-66-2 14986
10
Rivaroxaban Approved Phase 4 366789-02-8
11
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
12
Dalteparin Approved Phase 4 9005-49-6
13
Enoxaparin Approved Phase 4 9005-49-6 772
14
Methyclothiazide Approved Phase 4 135-07-9 4121
15
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
16
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
17
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
18
Mycophenolic acid Approved Phase 4 24280-93-1 446541
19
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
20
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
21
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
22
Desflurane Approved Phase 4 57041-67-5 42113
23
Acetaminophen Approved Phase 4 103-90-2 1983
24
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
25
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
26
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
27
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
28
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
29
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-02-9 14985
30
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
31
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
32 Tocotrienol Investigational Phase 4,Phase 3 6829-55-6
33 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Anesthetics Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
36 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Anti-Bacterial Agents Phase 4,Phase 1,Phase 2,Not Applicable
38 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Antitubercular Agents Phase 4,Not Applicable
42 Methylprednisolone Acetate Phase 4
43 Antibiotics, Antitubercular Phase 4,Phase 1,Phase 2,Not Applicable
44 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
45 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Early Phase 1
48 Prednisolone acetate Phase 4
49 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Early Phase 1
50 Central Nervous System Depressants Phase 4,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 363)
# Name Status NCT ID Phase Drugs
1 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis Unknown status NCT00265252 Phase 4 Alendronate
2 W-Shaped Acetabular Angular Plate (WAAP) Versus Reconstruction Plate Unknown status NCT02327949 Phase 4
3 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
4 Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings Completed NCT01806766 Phase 4
5 A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients Completed NCT01345097 Phase 4
6 Ultra-Short Anatomic and Conventional Cementless Stems Cementless Stems in Patients Younger Than Fifty-Five Years Old Completed NCT02338596 Phase 4
7 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed NCT02139007 Phase 4 Alendronate
8 Management of Mandibular ORN: PENTO as Medical Treatment Completed NCT02368457 Phase 4 Pentoxifylline and Tocopherol
9 Ceramic-on-Ceramic Versus Ceramic-on-HXLPE THA Completed NCT03639532 Phase 4
10 Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty Completed NCT02379663 Phase 4 Rivaroxaban;Enoxaparin
11 Benefit of Orthopedic Navigation in the ARThroplasty of the Hip Completed NCT01496300 Phase 4
12 Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease Completed NCT00364858 Phase 4 Cerezyme
13 The 3DKneeâ„¢ System: A Post-Market Study Completed NCT00764673 Phase 4
14 A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement Completed NCT00872066 Phase 4
15 A Randomised Single Centre Study to Compare the Long-term Wear Characteristics of Marathonâ„¢ and Enduronâ„¢ Polyethylene Cup Liners in Primary Total Hip Replacement Completed NCT00208442 Phase 4
16 Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation Completed NCT00724022 Phase 4 Basiliximab, Tacrolimus, MMF, Prednisolon;Basiliximab, Tacrolimus, MMF;Tacrolimus, MMF, rATG
17 Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI Recruiting NCT02893293 Phase 4 Ferumoxytol-enhanced magnetic resonance imaging
18 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
19 Post Approval Study: NOVATION Ceramic Articulation Hip System Recruiting NCT00715143 Phase 4
20 Opioid-Free Shoulder Arthroplasty Active, not recruiting NCT03540030 Phase 4 Gabapentin;Celecoxib;toradol;acetaminophen;regional block;propofol;IV lidocaine;rocuronium;vecuronium;sevoflurane;desflurane
21 A Randomised Single Centre Study to Compare the Long-term Performance of Acrylocâ„¢ and Palacos® R Bone Cements in Primary Total Hip Replacement Terminated NCT00208403 Phase 4
22 Trilogy AB Acetabular Hip System Post Approval Study Terminated NCT00715026 Phase 4
23 Post-approval Study of the DURALOC® Option Ceramic-on-Ceramic Hip Prosthesis System Terminated NCT00546598 Phase 4
24 Clinical Study Comparing Two Implant Surface Finishes in Patients Undergoing Cementless Total Hip Replacement Terminated NCT00306917 Phase 4
25 Multi-centre Study to Assess the Long-term Performance of the Deltamotion Cup System in Primary Hip Replacement Surgery Terminated NCT01635166 Phase 4
26 An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMAâ„¢ Hip in Primary Total Hip Replacement Terminated NCT01134445 Phase 4
27 A Randomised Study to Compare Metal Ion Release and Long-term Performance of the Pinnacleâ„¢ Cup With a Ceramic-on-Metal or a Metal-on-Metal Bearing Terminated NCT00873444 Phase 4
28 A Multi-centre Study to Assess the Long-term Performance of the DePuy PROXIMAâ„¢ Hip in Primary Total Hip Replacement Terminated NCT00208455 Phase 4
29 Metal on Metal Versus Metal on Highly Crossed Linked Polyethylene Sytem Terminated NCT01422564 Phase 4
30 A Single Centre Study to Assess the Long-term Performance of the DePuy ASRâ„¢ System in Primary Hip Resurfacing Surgery Terminated NCT00872794 Phase 4
31 A Two Centre Study to Assess the Stability and Long-term Performance of the C-Stemâ„¢ AMT in a Total Primary Hip Replacement Terminated NCT00872573 Phase 4
32 Multi-Centre Study to Assess the Long-term Performance of the DePuy ASRâ„¢ System in Resurfacing and Primary Total Hip Replacement Terminated NCT00872547 Phase 4
33 A Single Centre Study to Assess the Long-term Performance of the Pinnacleâ„¢ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement Terminated NCT00872222 Phase 4
34 A Multi-centre Study to Assess the Long-term Performance of the Summitâ„¢ Hip in Primary Total Hip Replacement Terminated NCT00208390 Phase 4
35 A Multi-centre Study to Assess the Long-term Performance of the DePuy ASRâ„¢ System in Primary Hip Resurfacing Surgery Terminated NCT00208377 Phase 4
36 A Two Centre Study to Assess the Long-term Performance of the Pinnacleâ„¢ Cup With a Metal-on-Metal Bearing in Primary Total Hip Replacement Terminated NCT00208364 Phase 4
37 Optetrak Posterior Stabilized Versus Optetrak Hi-Flex Withdrawn NCT00808613 Phase 4
38 A Multi-centre Study to Assess the Long-term Performance of the Pinnacleâ„¢ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip Replacement Withdrawn NCT00208429 Phase 4
39 Implantation of Bone Marrow Cells to Treat Avascular Necrosis of Femoral Head (ANFH) Unknown status NCT01613612 Phase 2, Phase 3
40 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
41 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
42 Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head Completed NCT00505219 Phase 3
43 Study Into the Effect of Ibandronate for the Treatment of Bone Marrow Edema in Relation to Spontaneous or Non-traumatic Osteonecrosis of the Knee: A Randomized Double-blind, Placebo-controlled Trial Completed NCT00532220 Phase 3 Ibandronate IV;Placebo
44 Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head Completed NCT00939900 Phase 3 zoledronic acid (aclasta)
45 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis Completed NCT00523341 Phase 3
46 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Completed NCT00869206 Phase 3 zoledronic acid
47 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
48 Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee Completed NCT02697773 Phase 3
49 Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone Completed NCT01924286 Phase 3 Prednisone;Placebo
50 Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee. Completed NCT02709486 Phase 3 Tanezumab;Tanezumab;Placebo

Search NIH Clinical Center for Osteonecrosis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteonecrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteonecrosis:
JACC, cultured cartilage for chondral lesion
PREOB, autologous osteoblasts for bone disorders
Embryonic/Adult Cultured Cells Related to Osteonecrosis:
Cultured cartilage (JACC�) PMIDs: 16233778 19393556 10738867 16226641 11284883 12043781 16233853 19802670 10679677

Cochrane evidence based reviews: osteonecrosis

Sources

Genetic Tests for Osteonecrosis

About this section

Genetic tests related to Osteonecrosis:

# Genetic test Affiliating Genes
1 Aseptic Necrosis 30
Sources

Anatomical Context for Osteonecrosis

About this section

MalaCards organs/tissues related to Osteonecrosis:

42
Bone, Bone Marrow, Testes, Endothelial, Skin, Kidney, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Osteonecrosis:

20
Bone
Sources

Publications for Osteonecrosis

About this section

Articles related to Osteonecrosis:

(show top 50) (show all 3646)
# Title Authors Year
1
Abdominal decompression illness following repetitive diving: a case report and review of the literature. ( 31051069 )
2019
2
Necrotizing fasciitis as a complication of osteonecrosis of the jaw related to oral bisphosphonate application in a patient with osteoporosis: a case report. ( 30288621 )
2019
3
Corticosteroid dose increase is a risk factor for nonalcoholic fatty liver disease and contralateral osteonecrosis of the femoral head: a case report. ( 30782153 )
2019
4
Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. ( 30794689 )
2019
5
Discrepant hypoxia tolerance aggravates subchondral delamination in osteonecrosis of the femoral head. ( 30448884 )
2019
6
Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia: Early Diagnosis and New Treatment Strategies. ( 30842156 )
2019
7
Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus. ( 30521019 )
2019
8
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG). ( 30131583 )
2019
9
Actinomyces Orbital Osteomyelitis in the Setting of Multiple Myeloma and Bisphosphonate-Related Osteonecrosis. ( 30763286 )
2019
10
Short-term outcomes after anatomic total shoulder arthroplasty in patients with osteoarthritis versus osteonecrosis. ( 30906752 )
2019
11
Does unicompartmental knee arthroplasty have worse outcomes in spontaneous osteonecrosis of the knee than in medial compartment osteoarthritis? A systematic review and meta-analysis. ( 30680456 )
2019
12
A novel FAM20C mutation causing hypophosphatemic osteomalacia with osteosclerosis (mild Raine syndrome) in an elderly man with spontaneous osteonecrosis of the knee. ( 30151622 )
2019
13
Comparative evaluation of SPECT/CT and CBCT in patients with mandibular osteomyelitis and osteonecrosis. ( 30806799 )
2019
14
Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis. ( 30832685 )
2019
15
Comparison of the histopathological characteristics of osteomyelitis, medication-related osteonecrosis of the jaw, and osteoradionecrosis. ( 30054185 )
2019
16
Osteonecrosis of Femoral Head is Associated with Congenital Multiple Pituitary Hormone Deficiency: Report of Three Cases and Literature Review. ( 30966827 )
2019
17
Huo Xue Tong Luo capsule ameliorates osteonecrosis of femoral head through inhibiting lncRNA-Miat. ( 30970282 )
2019
18
Case report of atypical osteonecrosis of the jaws: a clinical dilemma. ( 30975513 )
2019
19
Vascularized Second Metacarpal Bone Graft for the Treatment of Idiopathic Osteonecrosis of the Capitate. ( 30983413 )
2019
20
Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. ( 30984311 )
2019
21
Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. ( 30993010 )
2019
22
Association between genetic polymorphisms and osteonecrosis in steroid treatment populations: a detailed stratified and dose-response meta-analysis. ( 30996113 )
2019
23
Comparison of findings of radiographic and fractal dimension analyses on panoramic radiographs of patients with early-stage and advanced-stage medication-related osteonecrosis of the jaw. ( 31005615 )
2019
24
Low-Intensity Pulsed Ultrasound Prevents Development of Bisphosphonate-Related Osteonecrosis of the Jaw-Like Pathophysiology in a Rat Model. ( 31006496 )
2019
25
Association between NOS3 polymorphisms and osteonecrosis of the femoral head. ( 31007072 )
2019
26
Osteonecrosis of the jaws produced by sunitinib: a systematic review. ( 31011143 )
2019
27
Medication-Related Osteonecrosis of the Jaws: Two Center Retrospective Cohort Studies. ( 31011580 )
2019
28
Rapid Onset of Femoral Head Osteonecrosis after a Single Intraarticular Hip Joint Injection of Corticosteroid - A Case Report. ( 31021821 )
2019
29
Strategies to Avoid Osteonecrosis in Unstable Slipped Capital Femoral Epiphysis: A Critical Analysis Review. ( 31021894 )
2019
30
Pharmacogenomics of osteonecrosis of the jaw. ( 31022475 )
2019
31
A case report of Bisphosphonate Related Osteonecrosis of the Jaw treated by photodynamic therapy. ( 31022581 )
2019
32
Comparison of sartorius muscle-pedicle and circumflex iliac deep bone flap grafts in the treatment of early non-traumatic osteonecrosis of femoral head in young adults. ( 31031129 )
2019
33
Retrospective Long-Term Follow-Up Survival Analysis of the Management of Osteonecrosis of the Femoral Head With Pedicled Vascularized Iliac Bone Graft Transfer. ( 31031157 )
2019
34
Medication-related osteonecrosis of the jaw. Implant presence-triggered osteonecrosis: Case series and literature review. ( 31035023 )
2019
35
Surgical Management of Medication-Related Osteonecrosis of the Jaw Is Associated With Improved Disease Resolution: A Retrospective Cohort Study. ( 31054989 )
2019
36
Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. ( 31059548 )
2019
37
Preventing medication-related osteonecrosis of the jaw. ( 31068319 )
2019
38
Reply to: Osimertinib and jaw osteonecrosis? A case report. ( 31074838 )
2019
39
Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw. ( 31080196 )
2019
40
Osimertinib and jaw osteonecrosis? A Case Report. ( 31081942 )
2019
41
Vascularized Iliac Bone Flap Transfer for Early and Middle Stages of Osteonecrosis of the Femoral Head. ( 31086723 )
2019
42
Genetic predisposition for medication-related osteonecrosis of the jaws: a systematic review. ( 31097230 )
2019
43
Full blood counts are not predictive of the risk of medication-related osteonecrosis of the jaws: a case-control study. ( 31097394 )
2019
44
Response to Comment-Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology. ( 31100871 )
2019
45
Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation. ( 31106139 )
2019
46
Association of TIMP4 gene variants with steroid-induced osteonecrosis of the femoral head in the population of northern China. ( 30697482 )
2019
47
Volume of hip synovitis detected on contrast-enhanced magnetic resonance imaging is associated with disease severity after collapse in osteonecrosis of the femoral head. ( 30697641 )
2019
48
IL-4 gene polymorphisms and their relation to steroid-induced osteonecrosis of the femoral head in Chinese population. ( 30697966 )
2019
49
The radiological and clinical follow-up of osteonecrosis in cancer patients. ( 30698062 )
2019
50
Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication). ( 30705708 )
2019
Sources

Variations for Osteonecrosis

About this section
Sources

Expression for Osteonecrosis

About this section
Search GEO for disease gene expression data for Osteonecrosis.
Sources

Pathways for Osteonecrosis

About this section

Pathways related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Selenium Micronutrient Network 1
Show member pathways
 12.1 F2 MTHFR PLG SERPINE1 TNF
2
Formation of Fibrin Clot (Clotting Cascade) 67
Show member pathways
 12 F2 PLG SERPINC1 SERPINE1
3
Complement and coagulation cascades 1 38
11.92 F2 PLG SERPINC1 SERPINE1
4
Osteoclast differentiation 38
11.87 ACP5 TNF TNFRSF11B TNFSF11
5
AGE-RAGE signaling pathway in diabetic complications 38
11.76 SERPINE1 TNF VEGFA
6
Parathyroid hormone synthesis, secretion and action 38
11.76 BGLAP PTH RUNX2 TNFSF11
7
Rheumatoid arthritis 38
11.66 ACP5 TNF TNFSF11 VEGFA
8
HIF-1-alpha transcription factor network 1
11.54 ABCB1 SERPINE1 VEGFA
9
Cell adhesion_ECM remodeling 23
11.5 COL2A1 PLG SERPINE1
10
TGF-beta Receptor Signaling (WikiPathways) 1
11.46 RUNX2 SERPINE1 TNF
11
Differentiation Pathway 1
11.37 DKK1 TNFSF11 VEGFA
12
Endochondral Ossification 1
11.37 COL2A1 PTH RUNX2 VEGFA
13
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 23
11.05 BGLAP PTH RUNX2 TNFSF11
14
Sirolimus Pathway, Pharmacokinetics/Pharmacodynamics 62
10.77 ABCB1 CYP2C8
15
Warfarin Pathway, Pharmacodynamics 62
10.77 BGLAP F2
16
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
10.75 BGLAP PTH RUNX2 TNF TNFRSF11B TNFSF11
17
Osteoclast Signaling 1
10.7 ACP5 TNFRSF11B TNFSF11
18
BMP2-WNT4-FOXO1 Pathway in Human Primary Endometrial Stromal Cell Differentiation 1
10.69 BMP2 DKK1
19
Dissolution of Fibrin Clot 67
10.68 PLG SERPINE1
20
Taxane Pathway, Pharmacokinetics 62
10.67 ABCB1 CYP2C8
21
Osteoblast Signaling 1
10.4 BGLAP PTH TNFRSF11B TNFSF11
Sources

GO Terms for Osteonecrosis

About this section

Cellular components related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.77 ABCB1 BMP2 PLG TNF VEGFA
2 extracellular region GO:0005576 9.77 BGLAP BMP2 COL2A1 DKK1 F2 PLG
3 endoplasmic reticulum lumen GO:0005788 9.62 BGLAP COL2A1 F2 SERPINC1
4 collagen-containing extracellular matrix GO:0062023 9.56 COL2A1 PLG SERPINC1 SERPINE1
5 extracellular space GO:0005615 9.44 BGLAP BMP2 COL2A1 DKK1 F2 PLG
6 platelet alpha granule lumen GO:0031093 9.33 PLG SERPINE1 VEGFA

Biological processes related to Osteonecrosis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.88 COL2A1 SERPINE1 TNF TNFRSF11B
2 response to drug GO:0042493 9.85 ABCB1 BGLAP MTHFR PTH TNFRSF11B
3 positive regulation of gene expression GO:0010628 9.85 BMP2 DKK1 RUNX2 TNF TNFSF11 VEGFA
4 positive regulation of protein phosphorylation GO:0001934 9.83 BMP2 F2 TNF VEGFA
5 osteoblast differentiation GO:0001649 9.81 BGLAP BMP2 RUNX2
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.78 TNF TNFRSF11B TNFSF11
7 positive regulation of MAP kinase activity GO:0043406 9.75 TNF TNFSF11 VEGFA
8 bone development GO:0060348 9.72 BGLAP COL2A1 TNFSF11
9 hemostasis GO:0007599 9.71 F2 PLG SERPINC1
10 chondrocyte differentiation GO:0002062 9.67 BMP2 COL2A1 RUNX2
11 cellular response to BMP stimulus GO:0071773 9.65 BMP2 COL2A1 RUNX2
12 positive regulation of ossification GO:0045778 9.63 BMP2 PTH
13 positive regulation of blood coagulation GO:0030194 9.63 F2 SERPINE1
14 skeletal system development GO:0001501 9.63 BGLAP BMP2 COL2A1 PTH RUNX2 TNFRSF11B
15 regulation of blood coagulation GO:0030193 9.62 F2 SERPINC1
16 response to inorganic substance GO:0010035 9.62 BGLAP TNFRSF11B
17 negative regulation of cardiac muscle cell differentiation GO:2000726 9.61 BMP2 DKK1
18 bone resorption GO:0045453 9.61 ACP5 PTH TNFSF11
19 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.6 BMP2 RUNX2
20 proteoglycan metabolic process GO:0006029 9.59 BMP2 COL2A1
21 fibrinolysis GO:0042730 9.58 F2 PLG SERPINE1
22 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.56 BMP2 RUNX2
23 bone mineralization GO:0030282 9.51 BGLAP BMP2
24 regulation of osteoclast differentiation GO:0045670 9.5 BGLAP TNF TNFSF11
25 negative regulation of fibrinolysis GO:0051918 9.43 F2 PLG SERPINE1
26 ossification GO:0001503 9.43 ACP5 BGLAP BMP2 COL2A1 RUNX2 TNFSF11
27 regulation of signaling receptor activity GO:0010469 9.28 BMP2 DKK1 F2 PTH SERPINE1 TNF
28 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 BMP2 PTH RUNX2 SERPINE1 TNF TNFSF11

Molecular functions related to Osteonecrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.43 SERPINC1 SERPINE1 TNF
2 growth factor activity GO:0008083 9.26 BMP2 DKK1 F2 VEGFA
3 co-receptor binding GO:0039706 9.16 BMP2 DKK1
4 cytokine activity GO:0005125 9.02 BMP2 TNF TNFRSF11B TNFSF11 VEGFA
Sources

Sources for Osteonecrosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....